Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV

Cobicistat as a Pharmacoenhancer in Pregnancy and Postpartum: Progress to Date and Next Steps

(2019) Ahizechukwu C. Eke et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Reduced exposure to darunavir and cobicistat in HIV ‐1‐infected pregnant women receiving a darunavir/cobicistat‐based regimen

(2019) HM Crauwels et al.   HIV MEDICINE

Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV

(2019) Binh Nguyen et al.   ANNALS OF PHARMACOTHERAPY

Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice

(2019) José Ramón Santos et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Cobicistat-containing antiretroviral regimens are not recommended during pregnancy

(2019) Sarita D. Boyd et al.   AIDS

Evaluation of improved oral bioavailability of ritonavir nanosuspension

(2019) Alptug Karakucuk et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment

(2019) Yuqing Gong et al.   Expert Opinion on Drug Metabolism & Toxicology

Drug interaction after ritonavir discontinuation: considerations for antiretroviral therapy changes in renal transplant recipients

(2019) Humberto R Jimenez et al.   INTERNATIONAL JOURNAL OF STD & AIDS

Ritonavir- or cobicistat-boosted antiretroviral therapy and direct oral anticoagulants: A case for apixaban

(2019) Sarah A Nisly et al.   INTERNATIONAL JOURNAL OF STD & AIDS

No Inhibition of MATE1/2K-Mediated Renal Creatinine Secretion Predicted With Ritonavir or Cobicistat

(2019) Ryota Kikuchi et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Nanotechnology approaches for delivery of cytochrome P450 substrates in HIV treatment

(2019) Yuqing Gong et al.   Expert Opinion on Drug Delivery

Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination

(2018) Robin Augustine et al.   Acta Biomaterialia

Pharmacokinetic Differences Between Cobicistat and Ritonavir on Warfarin

(2018)   ANNALS OF PHARMACOTHERAPY

Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites

(2018) Niloufar Marsousi et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps

(2018) Ruben van der Galiën et al.   CLINICAL PHARMACOKINETICS

Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel

(2018) Matti K Itkonen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The HIV protease inhibitor, ritonavir, dysregulates human platelet function in vitro

(2018) Shannon G. Loelius et al.   THROMBOSIS RESEARCH

Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia

(2017) P Echeverría et al.   HIV MEDICINE

Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference

(2017) Cristina Gervasoni et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients

(2017) José Moltó et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat

(2017) Md Amin Hossain et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies

(2017) Narasimha M. Midde et al.   PHARMACEUTICAL RESEARCH

Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells

(2017) Narasimha M. Midde et al.   PLoS One

Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers

(2016) Lori A. Gordon et al.   CIRCULATION

HIV and aging

(2016) Edward J. Wing   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects

(2016) Srini Ramanathan et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications

(2016) Catia Marzolini et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method

(2016) Narasimha M. Midde et al.   PLoS One

Increasing use of ‘party drugs’ in people living with HIV on antiretrovirals

(2015) Margherita Bracchi et al.   AIDS

An unexpected interaction between warfarin and cobicistat-boosted elvitegravir

(2015) Brittany L. Good et al.   AIDS

Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations

(2015) Pavan Puligujja et al.   BIOMATERIALS

Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies

(2015) David J. Greenblatt et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection

(2015) Elizabeth M. Sherman et al.   CLINICAL THERAPEUTICS

Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles

(2015) Philip Martin et al.   MOLECULAR PHARMACEUTICS

Antiretroviral Pharmacokinetics in Pregnant Women

(2015) Elise M. Gilbert et al.   PHARMACOTHERAPY

Drug–drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems

(2014) Santosh Kumar et al.   Expert Opinion on Drug Metabolism & Toxicology

Cobicistat: a new opportunity in the treatment of HIV disease?

(2014) Amedeo Capetti et al.   EXPERT OPINION ON PHARMACOTHERAPY

Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects

(2014) Ivy Song et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results

(2013) Joel E. Gallant et al.   JOURNAL OF INFECTIOUS DISEASES

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection

(2011) Richard Elion et al.   AIDS

Differential Effects of Ethanol on Spectral Binding and Inhibition of Cytochrome P450 3A4 with Eight Protease Inhibitors Antiretroviral Drugs

(2011) Santosh Kumar et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572

(2011) Ivy Song et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR

(2010) Antonia H. Tolson et al.   ADVANCED DRUG DELIVERY REVIEWS

Pharmacokinetics, Efficacy, and Safety of Darunavir/Ritonavir 800/100 mg Once-Daily in Treatment-Naïve and -Experienced Patients

(2009) Marta Boffito et al.   HIV CLINICAL TRIALS

Dose–Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure

(2008) AA Mathias et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS